Last reviewed · How we verify
SHEN26 capsule
SHEN26 capsule is a vaccine that targets the SARS-CoV-2 spike protein.
SHEN26 capsule is a vaccine that targets the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.
At a glance
| Generic name | SHEN26 capsule |
|---|---|
| Sponsor | Shenzhen Kexing Pharmaceutical Co., Ltd. |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It works by inducing an immune response against the virus, which helps to prevent infection and disease. The exact mechanism of action is not fully understood, but it is thought to involve the activation of immune cells and the production of antibodies that can neutralize the virus.
Approved indications
- Prevention of COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19 (PHASE3)
- Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19 (PHASE2)
- A Phase I Study of SHEN26 Capsule in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHEN26 capsule CI brief — competitive landscape report
- SHEN26 capsule updates RSS · CI watch RSS
- Shenzhen Kexing Pharmaceutical Co., Ltd. portfolio CI